<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="59">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01204502</url>
  </required_header>
  <id_info>
    <org_study_id>06MI04</org_study_id>
    <nct_id>NCT01204502</nct_id>
  </id_info>
  <brief_title>Suicide Gene Therapy Trial</brief_title>
  <official_title>Phase I/II Clinical Trial of T-cell Suicide Gene Therapy Following Haploidentical Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Great Ormond Street Hospital for Children NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Great Ormond Street Hospital for Children NHS Trust</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone marrow or blood stem cell transplantation is used to treat a wide range of
      life-threatening conditions. T lymphocytes carried in the graft have powerful beneficial
      effects and play a vital role in the eradication of leukaemia and in fighting infection, but
      can also damage healthy tissues and cause graft-versus-host disease (GVHD).

      To safeguard against GVHD, the investigators propose modifying T cells to encode a 'switch'
      so that they can be eliminated if problems arise.

      Children receiving half-matched (haploidentical) transplants from a parent are most likely
      to benefit from this strategy. At present these patients receive blood stem cells from a
      parent, but the T cells are removed because the risk of serious GVHD is unacceptable. This
      means that they are much more likely to suffer from life threatening infections or
      experience a relapse of leukaemia. The investigators want to use gene therapy to produce
      &quot;safe&quot; T cells which can be used to strengthen the transplant and prevent these serious
      complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation:  Non-Randomized, Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Single Group Assignment, Masking:  Open Label, Primary Purpose:  Treatment</study_design>
  <primary_outcome>
    <measure>T-cell reconstitution (as defined by CD4+ cells &gt;300/mm3 &amp; CD3+ cells &gt;500/mm3)</measure>
    <time_frame>12 months after final dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>T-cell reconstitution is measured until 12 months after administration of the final dose of gene modified cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of GvHD</measure>
    <time_frame>12 months after final dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of GvHD is measured until 12 months after administration of the final dose of gene modified cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>12 months after final dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient survial is measured until 12 months after administration of the final dose of gene modified cells</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Haploidentical Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>HSVTK retrovirally-transduced donor T lymphocytes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD
dose 1 5x104 cells/kg
dose 2 5x105 cells/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HSVTK retrovirally-transduced donor T lymphocytes</intervention_name>
    <description>HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD
dose 1 5x104 cells/kg
dose 2 5x105 cells/kg</description>
    <arm_group_label>HSVTK retrovirally-transduced donor T lymphocytes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with primary immunodeficiencies, haematological malignancies or metabolic
             disorders at GOSH (children of both sexes, aged 0 to 16 years) undergoing
             haploidentical transplant

          2. Both patient and donor must give informed consent in writing.

          3. The donor must be willing, able and available for donation of T cells by collection
             of whole blood or leukapheresis.

          4. The patient should be free of serious intercurrent illness.

        Exclusion Criteria:

          1. Donor unfit or unavailable

          2. Donor positive for Hepatitis B or C, or HTLV-1, or HIV

          3. Patient receiving Ganciclovir, Aciclovir, Cidofovir a result of active CMV,
             adenovirus, varicella zoster or herpes simplex infection infection

          4. GVHD  â‰¥ grade II before infusion of gene modified T cells

          5. Serious intercurrent illness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anne-Marie McNicol, Dr</last_name>
    <phone>0207 905 2292</phone>
    <email>anne-marie.mcnicol@ich.ucl.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Waseem Qasim, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Qasim W, Gaspar HB, Thrasher AJ. T cell suicide gene therapy to aid haematopoietic stem cell transplantation. Curr Gene Ther. 2005 Feb;5(1):121-32. Review.</citation>
    <PMID>15638716</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <lastchanged_date>June 13, 2011</lastchanged_date>
  <firstreceived_date>September 16, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Biren Patel</name_title>
    <organization>Great Ormond Street Hospital for Children NHS Trust</organization>
  </responsible_party>
  <keyword>Gene therapy</keyword>
  <keyword>Haploidentical</keyword>
  <keyword>Bone marrow transplant</keyword>
  <keyword>Graft versus host disease</keyword>
  <keyword>haploidentical stem cell transplantation</keyword>
  <keyword>T-cell suicide gene therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suicide</mesh_term>
  </condition_browse>
</clinical_study>
